Who is sponsoring NCT03162926?

NCT03162926 is sponsored by ViaCyte.

What drugs are being tested in NCT03162926?

Interventions in NCT03162926: VC-02 Combination Product (aka PEC-Direct).

What condition does NCT03162926 study?

NCT03162926 studies Type 1 Diabetes Mellitus.

Is NCT03162926 still recruiting?

NCT03162926 is currently completed. Last updated 18 October 2018.

Last reviewed 2018-10-18 · How we verify

NCT03162926

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Completed Phase 1 Last updated 18 October 2018

What this trial tests

Phase 1 trial testing VC-02 Combination Product (aka PEC-Direct) in Type 1 Diabetes Mellitus in 3 participants. Completed in 15 February 2018.

Timeline

5 July 2017

Primary endpoint
15 February 2018

15 February 2018

Quick facts

Lead sponsor	ViaCyte
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	5 July 2017
Primary completion	15 February 2018
Estimated completion	15 February 2018
Sites	1 location across Canada

Drugs / interventions tested

VC-02 Combination Product (aka PEC-Direct)

Conditions studied

Type 1 Diabetes Mellitus — all drugs for Type 1 Diabetes Mellitus →

Sponsor

ViaCyte

Who can join

Adults 18 to 65, any sex, with Type 1 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Strategies for durable β cell replacement in type 1 diabetes.
Brusko TM, Russ HA, Stabler CL. · · 2021 · cited 107× · PMID 34326233 · DOI 10.1126/science.abh1657
Immunological considerations and challenges for regenerative cellular therapies.
Petrus-Reurer S, Romano M, Howlett S, Jones JL, et al · · 2021 · cited 97× · PMID 34172826 · DOI 10.1038/s42003-021-02237-4
Stem Cell-Based Clinical Trials for Diabetes Mellitus.
de Klerk E, Hebrok M. · · 2021 · cited 78× · PMID 33716982 · DOI 10.3389/fendo.2021.631463
Current state and future evolution of pancreatic islet transplantation.
Anazawa T, Okajima H, Masui T, Uemoto S. · · 2019 · cited 55× · PMID 30697608 · DOI 10.1002/ags3.12214
Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges.
Silva IBB, Kimura CH, Colantoni VP, Sogayar MC. · · 2022 · cited 53× · PMID 35840987 · DOI 10.1186/s13287-022-02977-y
Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks.
Martin U. · · 2017 · cited 50× · PMID 29312943 · DOI 10.3389/fmed.2017.00229
Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials.
Guhr A, Kobold S, Seltmann S, Seiler Wulczyn AEM, et al · · 2018 · cited 45× · PMID 30033087 · DOI 10.1016/j.stemcr.2018.06.012
Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?
Bourgeois S, Sawatani T, Van Mulders A, De Leu N, et al · · 2021 · cited 44× · PMID 33477961 · DOI 10.3390/cells10010191

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes Mellitus

Currently open trials in the same condition.

NCT07142252 — Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus · Phase 2 · recruiting
NCT07296276 — Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM · NA · recruiting
NCT07409701 — Gamification Intervertion in Children With Type 1 Diabetes · NA · recruiting
NCT07356089 — Twiist Postmarket Surveillance Study for Type 1 Diabetes · recruiting
NCT07434154 — Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults · recruiting

Other ViaCyte trials

Trials by the same sponsor.

NCT04678557 — A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus · Phase 1, PHASE2 · terminated
NCT03163511 — A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and H · Phase 1, PHASE2 · completed
NCT02939118 — One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™ · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03162926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ViaCyte
Last refreshed: 18 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03162926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing